Senior Resident, Dept. of Psychiatry, PGIMER, Chandigarh - 160 012, India.
Indian J Psychiatry. 2004 Apr;46(2):125-34.
Treatment resistance in schizophrenia is a fairly common problem faced by psychiatrists worldwide. The concept and definition of Treatment Resistant Schizophrenia (TRS) is still far from satisfactory. Data suggests the presence of biological factors underlying TRS. Second generation antipsychotics are advocated for patients with TRS. However, till date, clozapine remains the treatment of choice. Evidence for other pharmacological measures and ECT is accumulating. Psychosocial interventions do form an integral component of management of TRS. It can be concluded that, with advances in sychopharmacology, TRS needs to be better researched and managed in the future.
精神分裂症的治疗抵抗是全世界精神科医生面临的一个相当常见的问题。治疗抵抗性精神分裂症（TRS）的概念和定义仍远不能令人满意。数据表明，TRS 存在生物学因素。第二代抗精神病药被推荐用于 TRS 患者。然而，迄今为止，氯氮平仍然是治疗的首选。其他药物治疗措施和电惊厥治疗的证据也在不断增加。心理社会干预确实是 TRS 管理的一个组成部分。可以得出结论，随着精神药理学的进步，未来需要更好地研究和管理 TRS。
